Opioid switching from and to tapentadol extended release in cancer patients: Conversion ratio with other opioids

Current Medical Research and Opinion

Volumn 29, Issue 6, 2013, Pages 661-666

  Mercadante, Sebastiano ^a   Porzio, Giampiero ^b   Aielli, Federica ^b   Adile, Claudio ^a   Verna, Lucilla ^b   Ficorella, Corrado ^b   Giarratano, Antonello ^c   Casuccio, Alessandra ^c  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cancer pain; Conversion ratio; Opioid switching; Tapentadol

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; TAPENTADOL; TRAMADOL;

AGED; ANALGESIA; ARTICLE; CANCER PATIENT; CONVENIENCE SAMPLE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; HOME CARE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PROSPECTIVE STUDY;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; HUMANS; MORPHINE; NARCOTICS; NEOPLASMS; PAIN; PALLIATIVE CARE; PHENOLS; PROSPECTIVE STUDIES; RECEPTORS, OPIOID, MU;

EID: 84877295760     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.791617     Document Type: Article

References (22)

1. Mercadante S, Fulfaro F. World Health Organization guideline: a reappraisal. Ann Oncol 2005;16(Suppl 4):iv132-5
2. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-49
3. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68
4. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon Eur J Pain 2010;14:781-3
5. Schroder W, De Vry J, Tzeschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14:814-21
6. Shafer M. Novel concepts for analgesia in severe pain: current strategies and future innovations. Eur J Pain 2009;(Suppl 3):6-10
7. Cristoph T, De Vry J, Tzeschentke TM. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Let 2010;470:91-4
8. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo-and active-controlled phase III study. Exp Opin Pharmacother 2010;11:1787-814
9. Afilalo M, Etropolski M, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controller release for the management of moderate to severe chronic pain related to osteoarthritis of the knee. Clin Drug Invest 2010;30:489-505
10. Schwartz S, Etropolski M, Shapiro D, et al. Safety and efficacy of tapentadol SR in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled study. Curr Med Res Opin 2011;27: 151-62
11. Wild J, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Prac 2010;10:416-27
12. Mercadante S, Porzio G, Ferrera P, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012;28:1775-9
13. Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician 2013;16:27-40
14. Schroder W, De Vry J, Tzeschentke T, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14:814-21
15. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006;32:304-15
16. Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med 2011;25:494-503
17. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999;86:1856-66
18. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 2011;25:504-15
19. Mercadante S. Prospects and challenges in opioid analgesia for pain management. Curr Med Res Opin 2011;27:1741-3
20. Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol HCl. Drugs Future 2006;31:1053-61s
21. Mercadante S, Ferrera P, Adile C. Switching from methadone to tapentadol for cancer pain. A case report. J Pain Symptom Manage 2012; 44:e3-5
22. Mercadante S, Ferrera P, Villari P, et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009;37:632-41